25 results about "Cannabigerol" patented technology

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of PTE.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The utility model relates to industrial hemp extraction technical field, concretely relates to a hemp residue recovery and storage device based on industrial hemp extraction cannabigerol, including box, the inside assembly of box has the collecting device that carries out collection to impurity, the front of box is hinged with the box door, the collecting device includes roof, the roof fixed connection in the top of box, the fixed connection of electric telescopic link has in the roof inner wall bottom, the fixed connection of electric telescopic link output end bottom has the pressure plate, the fixed connection of box inner wall front has the supporting plate, the bottom of supporting plate inner wall is provided with the through -hole, the fixed connection of pressure plate top has the magnetism guide, the magnetism guide magnetic force is connected with permanent magnet. The utility model pressure plate presses down, magnetism guide and permanent magnet synchronous drop, rack drive first round tooth and second round tooth gear, first knock block and second knock block knock the sidewall of box and supporting plate bottom in proper order, through vibration stripping, solve the suspended and attached dust that traditional compression can not remove.

The invention provides a pharmaceutical formulation containing a particulate porous adsorbent selected from the group of aluminosilicates and their salts, with a neutral or basic pH and a particle size between 50 and 800 μm, onto which a mixture of polyoxyethylene sorbitan monooleate (polysorbate 80) is applied with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC, and D8-THC. This formulation improves the bioavailability and release profile of the cannabinoids.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

There is disclosed a composition comprising delta-9-tetrahydrocannabinol, cannabidiol, cannabigerol and a terpene component.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. These compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as their main components, which may be isolated, purified, or extracted from cultivars and mixed together. The compositions include CBD, CBG, and THC in specific proportions, formulated for use in the treatment of PTE.

This disclosure generally relates to gas-phase methods to simultaneously purify and decarboxylate cannabinoids in about two seconds, which are about 100-10,000 times more efficient than conventional purification and decarboxylation strategies. The methods also recover thermolabile cannabinoids such as cannabigerol at significantly higher yields than conventional methods.

A composition which provides a comprehensive solution for curbing, moderating and / or reducing the symptoms and cravings of opioid withdrawal syndrome. The composition is provided in the form of a capsule, pill, liquid, powder for mixing, or patch. In accordance with embodiments of the invention a composition for treating opioid withdrawal syndrome is provided. The composition includes (i) a therapeutically effective amount of a functional blend comprising a mixture of cannabidiol, cannabigerol, gamma aminobutyric acid, Inositol, and Vitamin B-12; (ii) a therapeutically effective amount of a hydration blend comprising a mixture of calcium, magnesium, potassium citrate, and L-glutamine; (iii) a therapeutically effective amount of an anti-inflammatory blend comprising a mixture of turmeric, green tea, and passion fruit; and (iv) a therapeutically effective amount of a neurotransmitter blend comprising 5-hydroxy-L-Tryptophan, N-acetyl L-Tyrosine, and L-Phenylalanine. The composition is consummate addition to a complete opioid cessation and withdrawal program because it targets, moderates, curbs and / or ameliorates the deleterious symptoms of opioid cessation and withdrawal. The composition is consummate addition to a complete opioid cessation and withdrawal program because it targets, moderates, curbs and / or ameliorates the potentially incessant drug cravings and the associated anxiety and stress.

This invention provides enzymes and methods for synthesizing cannabinoids specifically and in high yield. [Solution] A method is provided for producing one or more cannabinoids, comprising the step of contacting cannabigerol acid with a cannabinoid synthase ortholog. The cannabinoid synthase ortholog is derived from an organism other than hemp (Cannabis sativa). Also disclosed are recombinant cells of Saccharomyces cerevisiae or Pichia pastoris, which contain nucleic acids encoding the cannabinoid synthase ortholog in their genome. The cannabinoid synthase ortholog is expressed in its active form in the recombinant cells.

The application discloses a cannabinoid 1 type receptor-mediated brain-targeting lipid nanocapsule drug loading system and a preparation and application thereof, and belongs to the technical field of targeted drugs. The brain-targeting lipid nanocapsule drug loading system comprises a drug-loaded lipid nanocapsule, the surface of the lipid nanocapsule is modified with a ligand compound of a CB1 receptor, and the ligand compound is one of quebrachamine, methoxylated myristicin, chelerythrine, ostruthol or cannabigerol. The application utilizes the lipid nanocapsule carrier to load a compound X with neuroprotective activity, prolongs the circulation time of the compound X in the body, adsorbs a ligand compound Y on the surface of the lipid nanocapsule, can specifically recognize the CB1 receptor highly expressed on the brain nerve epidermal cells, can transport across the blood-brain barrier, and improves the drug concentration in the brain tissue and cells. The preparation method provided by the application is simple in operation, easy to popularize, can be used for preparing drugs crossing the blood-brain barrier, and has a wide application prospect.

Provided are pharmaceutical compositions comprising cannabis such that when combusted produces cannabidiolic acid (CBDA) for inhalation. Also provided are pharmaceutical composition for inhalation by a subject comprising tetrahy drocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), and cannabigerol (CBG). Also provided are methods of enhancing cannabidiolic acid (CBDA) in a pharmaceutical composition for inhalation. Methods of use of embodiments of the pharmaceutical composition and kits comprising embodiments of the pharmaceutical composition are provided herein. Unit dosage form medicaments and compositions for vaporization by a subject comprising cannabinoids are also disclosed herein.

This disclosure describes a cannabinoid-based nanoplatform for treating shingles, designed to enhance bioavailability and controlled release of active ingredients. The composition includes cannabinoids like cannabidiol (CBD) and cannabigerol (CBG), alongside flavonoids, polyphenols, and alkaloids, in oral and topical formulations. The oral capsule combines cannabinoids with polyphenols and flavonoids to provide systemic anti-inflammatory, antiviral, and neuroprotective effects, particularly for nerve pain and inflammation, including postherpetic neuralgia. The topical cream includes cannabinoids, capsaicin, and aloe vera, offering localized relief from pain, itching, and rash. The method targets both systemic and localized symptoms during the acute phase of shingles, aiming to inhibit varicella-zoster virus replication, disrupt viral assembly, and prevent viral release, while also providing immune modulation and anti-inflammatory benefits. The nanoplatform uses nano-emulsification techniques, producing particles smaller than 200 nm to ensure optimal delivery and therapeutic efficacy, offering comprehensive relief for shingles symptoms.

Cannabinoid compositions formulated for use in the treatment of complex regional pain syndrome (CRPS) are described. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as main components, which may be isolated, purified, or extracted from cultivars and blended together. The compositions include CBD, CBG, and THC in specific ratios, formulated for use in the treatment of CRPS.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, the composition comprising cannabigerol and rivocernib as active ingredients, and a use thereof. The composition according to the present invention is based on the finding that remarkably excellent cancer inhibitory efficacy is exhibited when rivoceranib and cannabigerol and / or cannabidiol are used in combination, and thus a cancer treatment effect can be enhanced using the composition.

The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and / or the reduction of melanin production in the skin, in particular for reducing pigmentation of the skin, preferably for the improvement of the appearance of the skin in case of hyperpigmentation, lentigo or vitiligo. Furthermore, the present invention relates to cannabigerol for use in a therapeutic method for the inhibition of tyrosinase activity and / or the reduction of melanin production in the skin, preferably for use in a therapeutic method for the treatment and / or prevention of malign skin disorders, in particular skin cancer.

The present disclosure relates to cannabigerol sulfonate esters of formula (1).

To provide enzymes and methods for synthesizing cannabinoids with specificity and a high yield.SOLUTION: Provided herein is a method for generating one or more cannabinoids, comprising a step of contacting cannabigerolic acid to a cannabinoid synthase ortholog. The cannabinoid synthase ortholog derives from organisms other than Cannabis sativa. Also disclosed is a recombinant cell of Saccharomyces cerevisiae or Pichia pastoris comprising a nucleic acid encoding the cannabinoid synthase ortholog in the genome. The cannabinoid synthase ortholog is expressed in the recombinant cell in an active form.SELECTED DRAWING: Figure 1

There is disclosed a composition comprising delta-9-tetrahydrocannabinol, cannabidiol, cannabigerol and a terpene component.

The present invention relates to a pharmaceutical composition comprising a tetrahydrocannabivarin (THCV), wherein the composition further comprises cannabigerol (CBG) or cannabinodiol (CBND) or a mixture thereof, for use in the prevention and treatment of overweight, preferably associated with obesitas. The pharmaceutical composition according to the invention may further comprise the following additional compounds tetrahydrocannabinol (THC), or Cannabigerol (CBG) or Cannabinodiol (CBND) or a combination thereof.

The present application refers to a composition comprising a therapeutically effective amount of cannabigerol and / or of a synthetic cannabigerol analogue for use in reducing: a) a frequency of calcium sparks in a cell, b) a number of calcium sparks per spark site in a cell, c) an intensity and / or a frequency of calcium waves in a cell, or d) any combination thereof. The present application also refers to said composition for use in the treatment and / or prevention of a cardiac arrhythmia.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The present invention relates to methods and pharmaceutical compositions for treating conditions in non-human mammals, including seizures, idiopathic epilepsy, anxiety, noise aversion, and separation anxiety. The treatment involves administering cannabinoid compositions comprising at least one cannabinoid selected from cannabidiol (CBD), cannabidivarin (CBDV), cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), and tetrahydrocannabivarin (THCV). Specific embodiments comprise CBD isolate nano-particles with purity greater than 99% of total cannabinoids and particle sizes less than 100 nanometers, suspended in oil-based media, essentially free of tetrahydrocannabinol (THC). Methods include acute treatment for noise aversion administered immediately prior to or during noise events, and daily administration for separation anxiety management. A pharmaceutical composition comprising CBD, CBDV, and CBC in a 5:1:1 weight ratio for treating seizures and idiopathic epilepsy is disclosed. The compositions may be administered orally, sublingually, or topically at dosages of 0.1 to 10 mg per kg body weight in cats, dogs, and horses.

Cannabigerol proline cocrystals are disclosed, specifically a 1:2 cannabigerol L-proline cocrystal, a 1:2 cannabigerol D-proline cocrystal and a 1:2 cannabigerol D, L-proline cocrystal and their preparation. Also disclosed are pharmaceutical compositions containing a cannabigerol proline cocrystal and a pharmaceutically acceptable excipient as well as methods and uses of a cannabigerol proline cocrystal or pharmaceutical composition to treat a disease, disorder or condition by administering to a patient in need thereof a therapeutically effective amount of a cannabigerol proline cocrystal or a pharmaceutical composition containing a cannabigerol proline cocrystal. Also disclosed are processes for the preparation of crystalline cannabigerol, Forms I, II and III.

Cannabinoid compositions formulated for use in the treatment of complex regional pain syndrome (CRPS) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of CRPS.